These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32313056)

  • 1. Improving Treatment Efficacy of In Situ Forming Implants via Concurrent Delivery of Chemotherapeutic and Chemosensitizer.
    Jeganathan S; Budziszewski E; Hernandez C; Dhingra A; Exner AA
    Sci Rep; 2020 Apr; 10(1):6587. PubMed ID: 32313056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.
    Sharma AK; Zhang L; Li S; Kelly DL; Alakhov VY; Batrakova EV; Kabanov AV
    J Control Release; 2008 Nov; 131(3):220-7. PubMed ID: 18722489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel polymer micelle mediated co-delivery of doxorubicin and P-glycoprotein siRNA for reversal of multidrug resistance and synergistic tumor therapy.
    Zhang CG; Zhu WJ; Liu Y; Yuan ZQ; Yang SD; Chen WL; Li JZ; Zhou XF; Liu C; Zhang XN
    Sci Rep; 2016 Mar; 6():23859. PubMed ID: 27030638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
    Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
    Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone (Dp44mT) overcomes multidrug resistance by a novel mechanism involving the hijacking of lysosomal P-glycoprotein (Pgp).
    Jansson PJ; Yamagishi T; Arvind A; Seebacher N; Gutierrez E; Stacy A; Maleki S; Sharp D; Sahni S; Richardson DR
    J Biol Chem; 2015 Apr; 290(15):9588-603. PubMed ID: 25720491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
    Toffoli G; Corona G; Gigante M; Boiocchi M
    Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversing Multidrug Resistance in Chemo-resistant Human Lung Adenocarcinoma (A549/DOX) Cells by Algerian Propolis Through Direct Inhibiting the P-gp Efflux-pump, G0/G1 Cell Cycle Arrest and Apoptosis Induction.
    Kebsa W; Lahouel M; Rouibah H; Zihlif M; Ahram M; Abu-Irmaileh B; Mustafa E; Al-Ameer HJ; Al Shhab M
    Anticancer Agents Med Chem; 2018; 18(9):1330-1337. PubMed ID: 30088453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced chemotherapy of cancer using pH-sensitive mesoporous silica nanoparticles to antagonize P-glycoprotein-mediated drug resistance.
    Huang IP; Sun SP; Cheng SH; Lee CH; Wu CY; Yang CS; Lo LW; Lai YK
    Mol Cancer Ther; 2011 May; 10(5):761-9. PubMed ID: 21411714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.
    Shen F; Bailey BJ; Chu S; Bence AK; Xue X; Erickson P; Safa AR; Beck WT; Erickson LC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):423-9. PubMed ID: 19423841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity.
    Szalóki G; Krasznai ZT; Tóth Á; Vízkeleti L; Szöllősi AG; Trencsényi G; Lajtos I; Juhász I; Krasznai Z; Márián T; Balázs M; Szabó G; Goda K
    PLoS One; 2014; 9(9):e107875. PubMed ID: 25238617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In situ forming implants exposed to ultrasound enhance therapeutic efficacy in subcutaneous murine tumors.
    Jeganathan S; Budziszewski E; Bielecki P; Kolios MC; Exner AA
    J Control Release; 2020 Aug; 324():146-155. PubMed ID: 32389777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
    Chen Y; Bathula SR; Li J; Huang L
    J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amphiphilic Copolymeric Micelles for Doxorubicin and Curcumin Co-Delivery to Reverse Multidrug Resistance in Breast Cancer.
    Lv L; Qiu K; Yu X; Chen C; Qin F; Shi Y; Ou J; Zhang T; Zhu H; Wu J; Liu C; Li G
    J Biomed Nanotechnol; 2016 May; 12(5):973-85. PubMed ID: 27305819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial circumvention of P-glycoprotein-mediated multidrug resistance by doxorubicin-14-O-hemiadipate.
    Leontieva OV; Preobrazhenskaya MN; Bernacki RJ
    Invest New Drugs; 2002 Feb; 20(1):35-48. PubMed ID: 12003193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
    Zahra R; Furqan M; Ullah R; Mithani A; Saleem RSZ; Faisal A
    PLoS One; 2020; 15(6):e0233993. PubMed ID: 32484843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo.
    Shen LZ; Hua YB; Yu XM; Xu Q; Chen T; Wang JH; Wu WX
    World J Gastroenterol; 2005 Feb; 11(7):1060-4. PubMed ID: 15742416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.
    Lopes de Menezes DE; Hu Y; Mayer LD
    J Exp Ther Oncol; 2003; 3(2):72-82. PubMed ID: 12822513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.
    Lopes EC; Scolnik M; Alvarez E; Hajos SE
    Leuk Res; 2001 Jan; 25(1):85-93. PubMed ID: 11137565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
    Krishna R; Mayer LD
    Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.